Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
273 Leser
Artikel bewerten:
(1)

Suvoda LLC: Suvoda Expands Clinical Trial Patient Travel Access Across the EU With Bolt Business Partnership

CONSHOHOCKEN, Pa., Oct. 7, 2025 /PRNewswire/ -- Suvoda (recently merged with Greenphire), a global clinical trial technology company specializing in software solutions to address trial complexity in the mission-critical, time-sensitive moments, today announced a partnership with Bolt Business a European mobility company, to expand cost-effective and accessible transportation options for clinical trial participants across the EU. This collaboration enables Suvoda's travel specialists to book Bolt rides for EU patients, with no out-of-pocket expenses to the patient, reducing logistical and financial burdens for participants and sites. Sites and sponsors can take advantage of the partnership by choosing Greenphire Travel, a product delivered on the Suvoda Platform.

Suvoda

"Patients in clinical trials already navigate complex health journeys without the added burden of unreliable transportation. Our partnership with Bolt Business reduces travel obstacles for patients which helps them stay enrolled in their trial, delivering the consistent patient retention that sites and sponsors need for successful trials," said Will Wing, Suvoda's Director of Product, Travel.

By providing a low-cost, reliable alternative to traditional car services while maintaining high standards of privacy and data security, this partnership will improve patient access across diverse trial populations.

"This partnership is built on Suvoda's and Bolt Business's shared commitment to removing barriers for clinical trial participants. It provides patients with flexible transport across EU markets, while giving Suvoda the cost control and account management support it needs. With Bolt's mobility options available, we're helping patients stay focused on their health journeys," said Liam James, Account Manager at Bolt Business.

The partnership is the latest example of Suvoda's investment in supporting global travel for clinical trial participants. Suvoda offers flexible and comprehensive travel service that includes:

  • Support provided to 8,400+ sites across 2,000+ studies in more than 50 countries
  • Expanded high-touch delivery model, including 90+ dedicated Concierge Coordinators offering personalized support for participants-geared towards rare and ultra rare disease trials
  • A 90% satisfaction rating among global sites

The new partnership follows Suvoda's successful merger with Greenphire in March 2025. The unified company brings best-in-class randomization, trial supply management, consent, patient engagement, financial support, and travel technologies under one platform-reflecting Suvoda's commitment to solving the most urgent and complex clinical trial challenges through integrated, seamless solutions.

About Suvoda
Suvoda is a global clinical trial technology company with a real-time experience platform that empowers sponsors and CROs to make confident decisions and sites and patients to take calm, controlled action. Suvoda delivers interconnected, action-driven software solutions and industry-leading services and support, so that even in the most time-sensitive, mission-critical moments, life-changing studies keep moving forward. Headquartered outside Philadelphia, Suvoda also maintains offices in Portland, OR, Barcelona, Spain, Bucharest and Iasi, Romania, and Tokyo, Japan. The company maintains customer satisfaction scores that consistently exceed the technology industry average, contributing to the company being selected by trial sponsors and CROs to support more than 2000 trials across more than 95 countries. Suvoda recently merged with Greenphire, a leading provider of clinical trial financial management and patient support tools. To learn more, visit suvoda.com. Follow Suvoda on LinkedIn.

CONTACT:
Robin Abadía
Director, External Communications
marketing@suvoda.com

Logo - https://mma.prnewswire.com/media/1759317/Suvoda_updated_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/suvoda-expands-clinical-trial-patient-travel-access-across-the-eu-with-bolt-business-partnership-302575887.html

© 2025 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.